首页> 外文期刊>Medical oncology >Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy
【24h】

Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy

机译:具有强度调制放疗和同时化疗的局部晚期肛管癌的管理

获取原文
获取原文并翻译 | 示例
           

摘要

The best curative option for locally advanced (stages II-III) squamous-cell carcinomas of the anal canal (SCCAC) is concurrent chemo-radiotherapy delivering 36-45 Gy to the prophylactic planning target volume with an additional boost of 14-20 Gy to the gross tumor volume with or without a gap-period between these two sequences. Although 3-dimensional conformal radiotherapy led to suboptimal tumor coverage because of field junctions, this modality remains a standard of care. Recently, intensity-modulated radiotherapy (IMRT) techniques improved tumor coverage while decreasing doses delivered to organs at risk. Sparing healthy tissues results in fewer severe acute toxicities. Consequently, IMRT could potentially avoid a gap-period that may increase the risk of local failure. Furthermore, these modalities reduce severe late toxicities of the gastrointestinal tract as well as better functional conservation of anorectal sphincter. This report aims to critically review contemporary trends in the management of locally advanced SCCAC using IMRT and concurrent chemotherapy.
机译:肛管(SCCAC)的局部晚期(阶段II-III)鳞状细胞癌的最佳治疗选择是同时进行化疗,以预防计划目标体积提供36-45 GY,额外提高14-20 GY至肿瘤大容量或其在这两个序列之间的间隙周期。虽然由于现场交叉点,3维保形放疗导致次优肿瘤覆盖率,但这种方式仍然是护理标准。最近,强度调节放疗(IMRT)技术改善了肿瘤覆盖,同时降低递送给风险的器官的剂量。保留健康组织导致更少的严重急性毒性。因此,IMRT可能会避免可能增加局部失败风险的差距。此外,这些方式降低了胃肠道的严重晚期毒性,以及肛门括约肌的更好的功能守恒。本报告旨在通过IMRT和同时化疗来批判地审查当地先进的SCCAC管理的当代趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号